Revolution in human health: End-to-end NGS workflow of Revvity

Revvity Pty Ltd
By Dohyun Kim
Saturday, 01 July, 2023

Revolution in human health: End-to-end NGS workflow of Revvity

Setting up a new lab or augmenting an existing one can be a daunting task. Once you have decided which tests you will offer and identified your lab space, you will need to set up a reliable, accurate workflow. Revvity’s complete NGS and other genomics workflows solutions improve the efficiency of your lab and offer flexibility should your needs change. Revvity offers solutions encompassing the entire workflow from sample to result.

Adaptable and scalable solutions for varying throughput

Revvity’s end to end solutions allow service labs to minimize errors, reduce hands-on time, and increase throughput and reproducibility. Flexible instrumentation modules, based on your testing and throughput requirements, can be added to meet your lab’s needs. Contact your Revvity sales representative for more information.

Sample flexibility

OMNI’s Bead Ruptor Elite™ Homogenizer coupled with sample specific bead milling materials ensure that a thorough homogenate is achieved regardless of the sample type. The high lysing efficiency of the Bead Ruptor Elite™ bead mill results in an increase in nucleic acid, protein and small molecules yields and increases the sensitivity of the downstream assay.


Automated high-throughput nucleic acid isolation

Based on the unique chemagen magnetic bead technology, the chemagic™ instruments enable the automated isolation of nucleic acids from sample materials such as buccal swabs, blood, saliva, sputum, serum or plasma with minimal hands-on time. The eluted high-quality nucleic acids are ready for subsequent analysis.


Versatile library prep automation

With flexibility in throughput, capacity and dynamic volume range, high quality manufacturing standards, and outstanding customer service and support, Revvity offers automated liquid handling solutions optimized to meet your laboratory’s needs.

More than 120 standardized and tested automated methods are available for the most frequently used NGS library prep kits. This extensive library of automated methods offers flexibility in the choice of kits. Additionally, Revvity’s team of application scientists is continuously releasing new automated methods to address emerging applications. By being responsive to latest trends in the NGS field, you can be assured we can meet your future automation needs.

Optimized library prep kits

Revvity provides a complete portfolio of NEXTFLEX® NGS library prep and barcodes for multiplexing designed to increase the flexibility and speed of library prep for Illumina® sequencing platforms. These kits offer increased enzymatic efficiency to achieve robust, sequencing data and cost-effective solutions for next generation sequencing library preparation.

Meaning Behind “Revvity”

Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure.​ Revvity was previously affiliated with PerkinElmer, Inc.

With “revolution” — rev — and “vita” (“life” in Latin) — vit — being rooted in our new name, Revvity represents our commitment to revolutionizing life through developing technologies and solutions for a healthier humankind. We are truly enthusiastic about this new beginning that builds upon decades of expertise and success across life sciences and diagnostics.

If you want to know more about “Revvity” please visit our website:

For more information about NGS Workflow, you can scan the QR code below.

For a larger version of the top image, click here.

Related Sponsored Contents

Dissociation of tumor tissue samples for single-cell genomics

Unraveling the diversity of cell types and understanding the complexity of the tumor...

Maximising Spatial Biology

An innovative new approach allows for the comprehensive examination of large tissue samples while...

Phasefocus Livecyte T-Cell Killing Assay tracks cancer cells and quantifies T-cell interactions

Most T-cell therapies fail in in vivo models and in clinical studies and therefore there is a...

  • All content Copyright © 2024 Westwick-Farrow Pty Ltd